Safety And Efficacy Of Krt-232 In Combination With Acalabrutinib In Subjects With R/?R Dlbcl Or R/?R Cll
Posted Date: Apr 26, 2024
- Investigator: John Byrd
- Specialties: Cancer, Lymphoma
- Type of Study: Drug
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Criteria:
Null
Keywords:
Chronic Lymphocytic Leukemia
For More Information:
Emily Greve
NULL
cancer@uchealth.com